Engimmune Therapeutics
1 known investors
Engimmune Therapeutics develops off-the-shelf soluble T-cell receptor (TCR) drugs to treat solid tumor cancers, using AI-guided protein engineering platforms to identify and engineer multi-specific TCRs. Its pipeline targets underserved oncology and autoimmune indications, with its lead asset in preclinical development.
AI & Machine LearningBiotechDeep Tech
Investors · 1
Frequently asked questions
- What does Engimmune Therapeutics do?
- Engimmune Therapeutics develops off-the-shelf soluble T-cell receptor (TCR) drugs to treat solid tumor cancers, using AI-guided protein engineering platforms to identify and engineer multi-specific TCRs. Its pipeline targets underserved oncology and autoimmune indications, with its lead asset in preclinical development.
- Who are Engimmune Therapeutics's investors?
- Engimmune Therapeutics's investors include Pureos Bioventures.